We are conducting FORTITUDE-HCM (NCT07023614), a global, multicenter Phase 2b clinical trial to evaluate the efficacy and safety of ninerafaxstat in non-obstructive hypertrophic cardiomyopathy (nHCM).
Phase 2a clinical trials have been completed in non-obstructive hypertrophic cardiomyopathy (nHCM) and cardiometabolic syndromes, including heart failure with preserved ejection fraction (HFpEF).
Imbria and third parties use cookies and similar technologies for site functions and analytics. We use optional cookies only if you accept. You can manage your choices at any time.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Google reCAPTCHA helps protect websites from spam and abuse by verifying user interactions through challenges.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com
You can find more information in our Privacy Policy.